Funded Project Details - FY2021
|Title:|| Understanding how DOPA decarboxylase modulates tau in disease|
|Congressional District Code:
||Biomedical Laboratory R&D
|| January 2019 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Background: Neurodegenerative diseases with tau pathology (tauopathies) include Alzheimer's disease and chronic traumatic encephalopathy. Two major risk factors for developing tauopathies are aging and repetitive mild traumatic brain injury. The prevalence of tauopathies is expected to rise, especially among Veterans. However, there are no clinically-approved treatments for tauopathies. DOPA decarboxylase, the second enzyme in dopamine and serotonin synthesis, was recently identified as a novel...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.